THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
97.03%
Total 13F principal
$206,163,706
Principal change
+$9,058,735
Total reported market value
$199,732,839
Number of holders
33
Value change
+$6,940,927
Number of buys
15
Number of sells
13

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q2 2018

As of 30 Jun 2018, THERAVANCE INC - CORPORATE OBLIG was held by 33 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $206,163,706 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, CNH PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, CALAMOS ADVISORS LLC, ADVENT CAPITAL MANAGEMENT /DE/, AMERIPRISE FINANCIAL INC, DEUTSCHE BANK AG\, SSI INVESTMENT MANAGEMENT INC, Castle Creek Arbitrage, LLC, and Opera Trading Capital. This page lists 33 institutional bondholders reporting positions for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.